Name: Latest research reports of Natco Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Natco Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Natco Pharma Ltd.

NSE: NATCOPHARM | BSE: 524816 | ISIN: INE987B01026 | Industry: Pharmaceuticals
| Strong Performer, Under Radar

875.1000 -6.50 (-0.74%)

NSE Jun 20, 2025 15:31 PM

46.61% Fall from 52W High

Volume: 592.9K

Natco Pharma Ltd.

14 Nov 2022

875.10

-0.74%

Stunted recovery mars performance

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco Pharma’s (Natco) Q2FY23 performance was lower than our estimates on all fronts. Revenue grew 14.6% YoY (-51.2% QoQ) to Rs4.3bn – below our expectation of
Rs5.6bn.

Geojit BNP Paribas increased Hold price target of Natco Pharma Ltd. to 952.0 on 11 Jun, 2025.